Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Change in Receivables (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Change in Receivables for 16 consecutive years, with $4.0 million as the latest value for Q4 2025.

Quarterly Change in Receivables rose 69.86% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $934000.0 through Dec 2025, up 195.89% year-over-year, with the annual reading at $934000.0 for FY2025, 195.89% up from the prior year.
Change in Receivables for Q4 2025 was $4.0 million at Harvard Bioscience, up from $210000.0 in the prior quarter.
The five-year high for Change in Receivables was $4.0 million in Q4 2025, with the low at -$2.8 million in Q2 2024.
Average Change in Receivables over 5 years is -$66800.0, with a median of -$214500.0 recorded in 2021.
The sharpest move saw Change in Receivables skyrocketed 210.53% in 2021, then crashed 897.32% in 2022.
Over 5 years, Change in Receivables stood at $3.6 million in 2021, then tumbled by 64.12% to $1.3 million in 2022, then decreased by 26.48% to $941000.0 in 2023, then soared by 147.5% to $2.3 million in 2024, then skyrocketed by 69.86% to $4.0 million in 2025.
According to Business Quant data, Change in Receivables over the past three periods came in at $4.0 million, $210000.0, and -$1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.